
Join to View Full Profile
550 1st AveBldg CddeptNew York, NY 10016
Phone+1 212-263-6485
Fax+1 732-235-7943
Dr. Omene is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Coral Omene is a medical oncologist, specializing in breast cancer and Associate Professor at Rutgers Cancer Institute in New Jersey. She has a passion for women’s health and is dedicated to the care and management of a diverse pool of breast cancer patients. She began her career upon completion of a combined MD/PhD degree at Columbia University College of Physicians and Surgeons. This was followed by an Internal Medicine residency at New York Presbyterian Hospital-Columbia University Medical Center. After residency, she pursued a fellowship at NYU School of Medicine, in the field of Hematology/Oncology, with a special interest in breast cancer. In addition to taking care of breast cancer patients, she conducts extensive translational and clinical research in breast cancer with a particular focus on the impact on cancer disparities. She is currently investigating the interplay with biology, obesity and treatment outcomes in both hormone receptor positive and triple negative breast cancer and the impact on cancer disparities and has developed clinical trials for these populations in this regard. She serves as the Program Director, Breast Cancer Disparities Research at Rutgers Cancer Institute. She is a Principal Investigator for numerous clinical trials and serves on multiple national committees including as the Co-Chair of the BIG Ten Cancer Research Consortium Breast Cancer Clinical Trial Working Group and Co-Chair of the BIG Ten CRC Health Equity Committee. She actively publishes in reputable journals such as JAMA and Nature Medicine and participates in local, regional, and national scientific conferences including the American Society of Clinical Oncology, American Association for Cancer Research, and the San Antonio Breast Cancer Symposium.
https://cinj.org/coral-o-omene-md-phd
https://www.ncbi.nlm.nih.gov/myncbi/1hSfgiIWN0GkY/bibliography/public/
Education & Training
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
- Columbia University Vagelos College of Physicians and SurgeonsClass of 2003
Certifications & Licensure
- NJ State Medical License 2017 - 2027
- NY State Medical License 2005 - 2017
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Jonas E. Salk Award, 1994
- Dean’s Scholar 1990-1994
- Physician Scientist Training Grant (PSTP), 2009
- Join now to see all
Clinical Trials
- Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2022 Sep 13
- Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer Start of enrollment: 2024 Nov 15
- Join now to see all
Publications & Presentations
PubMed
- Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors.Bo Qin, Madhir Vyas, Steven C Moore, Xiaoyang Su, Eileen P White
Cancer Epidemiology, Biomarkers & Prevention. 2025-06-03 - Associations between experiences of discrimination and quality of life in Black breast cancer survivors.Nur Zeinomar, Marley Perlstein, Bo Qin, Hari S Iyer, Jesse J Plascak
Cancer. 2025-04-15 - 13 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
Press Mentions
- Redefining Cancer Care Value: An Interview with Dr. Coral OmeneJune 8th, 2025
- Clinical Researchers Aim to Improve Breast Cancer Outcomes Through Sustainable and Effective Weight Loss in the FITWISE StudyApril 1st, 2025
- OP-ED: Breast Cancer Clinical Trials Are Missing Black WomenJanuary 23rd, 2025
- Join now to see all
Grant Support
- Modifying The Risk For Developing Triple Negative Breast Cancer (TNBC)NIH/NCIPresent
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: